On December 3, 2019 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) a biotechnology company specializing in the development of novel treatments for brain tumors, reported that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will be participating in the 12th Annual LD Micro Main Event Conference in Los Angeles, CA (Press release, CNS Pharmaceuticals, DEC 3, 2019, https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-12th-annual-ld-micro-main-event-conference-300967894.html [SID1234551900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

12th Annual LD Micro Main Event Conference

Format:

Presentation & 1×1 Meetings

Date:

Tuesday, December 10, 2019

Time:

4:20pm PT

Location:

Luxe Sunset Boulevard Hotel, Los Angeles, CA

About Berubicin
Berubicin is an anthracycline, a class of drugs among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to damage the DNA of targeted cancer cells by interfering with the action of the topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), the world’s largest cancer research facility. Berubicin appeared to demonstrate one Durable Complete Response in a Phase I human clinical trial conducted by a prior developer.